Xeris Biopharma transitioned to operating profitability in 2025 after years of substantial losses, supported by strong growth in its endocrine and neurological disease portfolio. Key commercial products Recorlev, Gvoke, and Keveyis contributed to a 44% revenue increase year-over-year. The company’s proprietary non-aqueous injection technologies underpin product differentiation and stability. While net income is modest and capital structure includes significant debt, cash flows have improved markedly, supporting ongoing R&D investments and commercial expansion. Challenges remain in defending patent exclusivity and advancing pipeline therapies, notably XP-8121 for hypothyroidism.